Fresh2 Group Beheer

Beheer criteriumcontroles 0/4

De CEO Fresh2 Group is Haohan Xu, benoemd in May2023, heeft een ambtstermijn van 1.5 jaar. bezit rechtstreeks 15.7% van de aandelen van het bedrijf, ter waarde $ 399.01K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 2.1 jaar.

Belangrijke informatie

Haohan Xu

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.5yrs
Eigendom CEO	15.7%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

AnPac Bio announces plan to implement ADS ratio change

Oct 18

AnPac Bio-Medical Science announces management changes

Oct 03

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

Sep 27

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Dec 14

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

Dec 11

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Nov 25

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

Nov 02

CEO

Haohan Xu (29 yo)

1.5yrs

Tenure

Mr. Haohan Xu serves as Chief Executive Officer at Fresh2 Group Limited since May 17, 2023. He served as Co-Chief Executive Officer of Fresh2 Group Limited until May 17, 2023 and serves as its Chairman of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Haohan Xu	Chairman of the Board & CEO	1.5yrs	geen gegevens	15.7% $ 399.0k
Xiaoyu Li	Director & CFO	1.3yrs	geen gegevens	geen gegevens
Weidong Dai	China President	9.6yrs	geen gegevens	geen gegevens
Sunil Pandit	U.S. Chief Executive Officer	3.3yrs	geen gegevens	geen gegevens
Yidong Hu	Chief Strategy Officer	1.3yrs	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

35yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FRES wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Haohan Xu	Chairman of the Board & CEO	2.1yrs	geen gegevens	15.7% $ 399.0k
Xiaoyu Li	Director & CFO	2.1yrs	geen gegevens	geen gegevens
Lee Shulman	Member of Technical Advisory Board	6.1yrs	geen gegevens	geen gegevens
Tianruo Pu	Independent Director	2.1yrs	geen gegevens	geen gegevens
Honggang Tian	Independent Director	2.1yrs	geen gegevens	geen gegevens
Zhigang Zhao	Independent Director	2.1yrs	geen gegevens	geen gegevens
Zhijun Liang	Independent Director	less than a year	geen gegevens	geen gegevens
Xiaohui Zhang	Independent Director	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

43yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FRES wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Fresh2 Group Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

Recent updates

New major risk - Financial data availability

High number of new and inexperienced directors

Fresh2 Group Limited Announces Receipt of A Delinquency Compliance Alert Notice from Nasdaq

Fresh2 Group Limited announced delayed annual 10-K filing

Fresh2 Group Ltd Launches TikTok Video E-commerce Venture, Bridging the Gap Between Food Sources and Consumers

Fresh2 Group Receives Deficiency Notice from the Nasdaq Regarding Fails to Comply with the $1 Minimum Bid Price Required for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Fresh2 Group Limited Appoints Zhijun (Michael) Liang as Independent Director, Effective January 1, 2024

Ningkasai Technology (Shanghai) Co., Ltd. entered into a share purchase agreement to acquire Changhe Bio-Medical Technology (Yangzhou) Co., Ltd. from Fresh2 Group Limited (NasdaqCM:FRES) for CNY 1.

Fresh2 Group Limited (NasdaqCM:FRES) acquired Roxe Holding Inc.

Fresh2 Group Limited Appoints Yidong Hu as Chief Strategy Officer

Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements

Fresh2 Group Limited Announces the Resignation of Chris Chang Yu as Co-Chief Executive Officer

AnPac Bio-Medical Science Co., Ltd. (NasdaqCM:ANPC) entered into an agreement to acquire Fresh2 Ecommerce Inc for $2.1 million.

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $5 million in funding

AnPac Bio-Medical Science Announces Regaining Compliance with Nasdaq Listing Requirement

AnPac Bio-Medical Science Co., Ltd. Announces Board Resignations

AnPac Bio Granted Continued Listing by Nasdaq Hearing Panel

AnPac Bio announces plan to implement ADS ratio change

Anpac Bio-Medical Science Co., Ltd. Appoints Xiaoyu Li as Chief Financial Officer

AnPac Bio-Medical Science announces management changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $3.67 million in funding

AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group

AnPac Bio-Medical Science Appeals Nasdaq Delisting Notice; Hearing Granted and Scheduled for October 20, 2022

AnPac Bio-Medical Science Co., Ltd. Appeals Nasdaq Delisting Notice

Less than half of directors are independent

AnPac Bio-Medical Science Co., Ltd. Announces Executive Appointments

AnPac Bio appoints Yuyang Cui as co-chief executive officer

AnPac Bio-Medical Science Co., Ltd. Approves CEO Changes

AnPac Bio-Medical Science Co., Ltd. announced that it expects to receive $1.5 million in funding

Anpac Bio-Medical Science Co., Ltd. Appoints Chris Chang Yu as Co-CEO of the Company

AnPac Bio-Medical Science Co., Ltd. announced delayed 20-F filing

High number of new directors

AnPac Bio-Medical Science Co., Ltd. Announces Executive Changes

AnPac Bio-Medical Science Announces Receipt of Staff Delisting Determination from Nasdaq

AnPac Bio-Medical Science Co., Ltd. Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in first quarter of 2022

Third quarter 2021 earnings: Revenues miss analyst expectations

Second quarter 2021 earnings released: CN¥2.16 loss per share (vs CN¥3.15 loss in 2Q 2020)

AnPac Bio-Medical Science Co., Ltd. Completes Major Preclinical Study, Files with National Medical Products Administration for Registration Testing of Its Multi-Cancer CDA Device

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.

Consensus revenue estimates fall to CN¥34.5m

First quarter 2021 earnings released: CN¥1.93 loss per share (vs CN¥2.56 loss in 1Q 2020)

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

Full year 2020 earnings released

New 90-day high: US$7.70

NMPA Approves Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)

AnPac Bio wins new US patent for multi-cancer detection

AnPac Bio-Medical Science Co., Ltd. Makes Significant Progress in Detecting Pre-Cancer Diseases and Recorded over 20 Types of Pre-Cancer Diseases

AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases

Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%

New 90-day high: US$7.14

AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%

Anpac Bio-Medical Science Co., Ltd. Appoints Jianhua Shao as Independent Director and Member of Compensation Committee

AnPac Bio-Medical Science Co., Ltd. Completes COVID-19 Antibody Test Verification

AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%

New 90-day low: US$3.38

New 90-day low: US$4.20

First half earnings released

New 90-day low - US$4.80

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd